Go Pro

BIOLASE (BIOL) 10K Form and Latest SEC Filings 2026

BIOLASE logo

Latest BIOLASE SEC Filings & Recent Activity

BIOLASE (NASDAQ:BIOL) has submitted 302+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form SEC STAFF ACTION submitted on April 21, 2025.

DateFilerForm TypeView
04/21/2025 11:00 AM
BIOLASE (811240) Filer
Form SEC STAFF ACTION
11/14/2024 6:20 PM
BIOLASE (811240) Subject
Lind Global Fund II LP (1871665) Filed by
Form SC 13G/A
11/14/2024 4:38 PM
Anson Funds Management LP (1491072) Filed by
BIOLASE (811240) Subject
Form SC 13G/A
11/07/2024 3:51 PM
BIOLASE (811240) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/08/2024 3:47 PM
BIOLASE (811240) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/06/2024 6:39 AM
BIOLASE (811240) Subject
Nasdaq Stock Market LLC (1354457) Filed by
Form 25-NSE
08/28/2024 3:05 PM
BIOLASE (811240) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/08/2024 3:30 PM
BIOLASE (811240) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
06/18/2024 5:06 AM
BIOLASE (811240) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/03/2024 4:17 PM
BIOLASE (811240) Filer
Form S-1
Registration statement under Securities Act of 1933  
05/17/2024 5:42 AM
BIOLASE (811240) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/23/2024 3:21 PM
BIOLASE (811240) Filer
Form 424B4
04/22/2024 11:15 PM
BIOLASE (811240) Filer
Form EFFECT
04/19/2024 4:07 PM
BIOLASE (811240) Filer
Form POS AM
04/19/2024 3:13 PM
BIOLASE (811240) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/11/2024 3:55 PM
BIOLASE (811240) Filer
Form POS AM
04/02/2024 11:15 PM
BIOLASE (811240) Filer
Form EFFECT
03/27/2024 3:43 PM
BIOLASE (811240) Filer
Form S-1/A
03/08/2024 5:31 AM
BIOLASE (811240) Filer
Form PRE 14A
03/05/2024 5:05 AM
BIOLASE (811240) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/21/2024 3:39 PM
BIOLASE (811240) Subject
Lind Global Fund II LP (1871665) Filed by
Form SC 13G
02/21/2024 6:01 AM
BIOLASE (811240) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2024 8:21 PM
BIOLASE (811240) Filer
Form 424B1
02/14/2024 12:10 PM
BIOLASE (811240) Subject
LYTTON LAURENCE W (1105806) Filed by
Form SC 13G/A
02/13/2024 7:03 PM
BIOLASE (811240) Subject
Lind Global Fund II LP (1871665) Filed by
Form SC 13G/A
02/09/2024 7:44 AM
BIOLASE (811240) Filer
Form S-1/A
02/07/2024 5:04 AM
BIOLASE (811240) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/07/2024 5:11 AM
BIOLASE (811240) Filer
Form S-1/A
01/30/2024 8:57 PM
BIOLASE (811240) Filer
Form S-1/A
01/24/2024 4:21 PM
BIOLASE (811240) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
01/19/2024 5:09 AM
BIOLASE (811240) Filer
Form S-1
Registration statement under Securities Act of 1933  
12/26/2023 4:22 PM
BIOLASE (811240) Filer
Form S-1
Registration statement under Securities Act of 1933  
12/20/2023 1:13 PM
BIOLASE (811240) Filer
Form D
Notice of Exempt Offering of Securities 
12/08/2023 8:23 AM
BIOLASE (811240) Filer
Form 424B5
12/08/2023 8:25 AM
BIOLASE (811240) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/09/2023 3:52 PM
BIOLASE (811240) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/09/2023 3:20 PM
BIOLASE (811240) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/10/2023 2:53 PM
BIOLASE (811240) Subject
Krefta Edson Roberto (1990589) Filed by
Form SC 13G/A
10/06/2023 4:25 PM
BIOLASE (811240) Issuer
GOLDMAN SACHS & CO. LLC (769993) Reporting
GOLDMAN SACHS GROUP INC (886982) Reporting
Form 3
Initial statement of beneficial ownership of securities  
09/15/2023 4:27 PM
BIOLASE (811240) Filer
Form 424B1
09/15/2023 4:27 PM
BIOLASE (811240) Filer
Form 424B1
Elon Musk’s Hushed FCC Filing. Sept 25th. (Ad)

Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.tc pixel

Click here to see details on Elon Musk's newest AI filing
09/14/2023 8:08 AM
BIOLASE (811240) Filer
Form POS EX
09/13/2023 11:15 PM
BIOLASE (811240) Filer
Form EFFECT
09/13/2023 8:25 PM
BIOLASE (811240) Filer
Form S-1MEF
09/12/2023 2:26 PM
BIOLASE (811240) Subject
Krefta Edson Roberto (1990589) Filed by
Form SC 13G
09/11/2023 4:09 PM
BIOLASE (811240) Filer
Form S-1/A
(Data available from 1/1/2016 forward)

BIOLASE SEC Filings - Frequently Asked Questions

BIOLASE (BIOL) has submitted 302+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

BIOLASE's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form SEC STAFF ACTION submitted on April 21, 2025. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:BIOL are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 4/21/2025. New filings are added as they're published.
From Our Partners